BHCM
SRPT icon

Brevan Howard Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Brevan Howard Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Sell
30,928
-2,242
-7% -$42.4K ﹤0.01% 1394
2026
Q1 		$722K Buy
33,170
+21,363
+181% +$413K 0.01% 1090
2025
Q4 		$254K Sell
11,807
-25,604
-68% -$540K ﹤0.01% 1456
2025
Q3 		$721K Buy
+37,411
New +$667K ﹤0.01% 1081
2025
Q2 		– Sell
-7,869
Closed -$502K – 2003
2025
Q1 		$502K Buy
7,869
+2,884
+58% +$304K ﹤0.01% 729
2024
Q4 		$606K Buy
4,985
+1,339
+37% +$164K ﹤0.01% 564
2024
Q3 		$455K Sell
3,646
-431
-11% -$59.6K ﹤0.01% 707
2024
Q2 		$644K Sell
4,077
-6,635
-62% -$852K 0.01% 526
2024
Q1 		$1.39M Buy
10,712
+2,653
+33% +$325K 0.01% 199
2023
Q4 		$777K Buy
8,059
+6,184
+330% +$593K 0.01% 316
2023
Q3 		$227K Buy
+1,875
New +$212K ﹤0.01% 301

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Brevan Howard Capital Management's SRPT Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 6.8% in Q2 2026, selling an estimated $42.4K and leaving 30,928 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #1394.

Brevan Howard Capital Management first reported a position in SRPT in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.39M in Q1 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Brevan Howard Capital Management held 30,928 shares of Sarepta Therapeutics worth $556K as of Q2 2026.
  • Brevan Howard Capital Management sold 2,242 Sarepta Therapeutics shares in Q2 2026, an estimated $42.4K.
  • Sarepta Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1394 holding.
  • Brevan Howard Capital Management first reported a position in Sarepta Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Brevan Howard Capital Management's Sarepta Therapeutics position peaked at $1.39M in Q1 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.